Phase 3 Trial of Aflibercept in Second-Line Metastatic Colorectal Cancer to Continue as Planned at Recommendation of Independent Data Monitoring Committee
[PR Newswire] - Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced today that the Phase 3 VELOUR clinical trial of aflibercept in patients with metastatic colorectal cancer will continue to completion as planned, with no modifications due to efficacy or safety concerns.  This decision is based on the recommendation of an Independent Data Monitoring Committee following a planned interim analysis.  Both sanofi-aventis and Regeneron management and staff remain blinded to the interim study results.

BMY to take ZGEN Under its Wings
[Zacks] - Bristol-Myers Squibb Company announced its decision to acquire ZymoGenetics Inc. for $9.75 per share in cash.

Perrigo To Nurture Infant Formula Biz As With Medication

Teva Wins Copaxone Protection